Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

Completed

Conditions studied: Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis

In brief

The objective of this study is to determine whether there is a relationship between interferon-gamma levels and the incidence of viral respiratory infections in allergic children treated with allergy immunotherapy as compared to those treated with standard medical care (nasal steroids, antihistamines) over a 1-year period. The hypotheses to be tested are 1) interferon-gamma levels will be significantly increased 3, 6, 9 and 12 months in allergic children treated with allergy immunotherapy as compared to those treated with standard medical care, 2) the incidence of viral respiratory infections will be reduced at 3, 6, 9 and 12 months in allergic children treated with allergy immunotherapy as compared to those treated with standard medical care.

Key facts

Study ID

NCT00405899

Run by

West Penn Allegheny Health System

People needed

20

Starts

2006-10-01

Expected to finish

2009-12-01

Last updated by the study team

2010-05-31

Who can join

Age: 6 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 6-18 years of age
• History of allergic rhinitis as confirmed by previous allergy skin testing conducted within the past year
• Subjects assigned to the allergy immunotherapy must be prescribed therapy according to national recommendations using FDA-approved allergy extracts supplied by Greer Laboratories

You may not qualify if…

• Concurrent difficult to control asthma or an underlying immune deficiency

Where it is running

• Allegheny General Hospital — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.